| Date | Title | Description |
| Sign up to see | Sign up to see | Sign up to see |
| May 14, 2026 | Crohn’s & Colitis Foundation’s 11th Annual BANDed Together Fundraiser Returns to Long Branch | Organizers of ADH BANDed Together pose in a throwback photo from 2025.
Live music from talented local musicians at last year’s event
A basket raffle, one of the highlights from 2025
The Foundation’s New Jersey Chapter Welcomes Guests, Spons... |
| Feb 19, 2026 | Vie Ventures Names Jeff Bluestone, PhD, As Managing Director | Vie Ventures, a life sciences venture capital firm focused on autoimmune and immune-mediated diseases, announced that Jeff Bluestone, PhD, has been named Managing Director. He joins founders Steven St. Peter, MD, and Luke Evnin, PhD, who al... |
| Oct 15, 2025 | Noted Mercy Gastroenterologist Dr. Raymond Cross Named 2025 Medical Champion Award Recipient by The Crohn's & Colitis Foundation | Mercy Medical Center gastroenterologist Dr. Raymond Cross named the 2025 Medical Champion of Hope honoree by The Crohn's & Colitis Foundation's DC/Maryland/Virginia (DMV) Chapter.
BALTIMORE, Oct. 14, 2025 /PRNewswire-PRWeb/ -- The Crohn... |
| Sep 30, 2025 | Johnson & Johnson Launches "Dual Control" Campaign in Asia Pacific to Empower Patients with IBD to Balance Disease Management and Dreams | New IBD research shows that, even during clinical remission, people living with Crohn's disease continue to experience greater work impairment than the general population
The new campaign aims to empower patients to take dual control of dis... |
| Nov 7, 2024 | Albany Gastroenterologist Dr. Jennifer Northrop Named Physician of the Year | 2024 Physician of the Year Dr. Jennifer Northrop & Chapter Sr. Executive Director Linda Winston
2024 Gala Honorees Dr. Jennifer Northrop and Larry and Nicole Treen
2024 An Evening to Remember Gala
The Crohn’s & Colitis Foundation Up... |
| Aug 7, 2024 | Local NJ Philanthropy Event Raises $75,000 for Digestive Disease Research | Penny Turtel, MD, Executive Director of the Crohn’s and Colitis New Jersey Chapter and Gastroenterologist at Shore Gastroenterology Associates with Dr. Michael Aquino.
The Allied Digestive Health team at the Crohn’s & Colitis Foundation... |
| Jun 4, 2024 | Azenta Announces Collaboration with the Crohn's & Colitis Foundation to Support its Crohn's Disease and Ulcerative Colitis Clinical Research | Azenta has been Selected by the Crohn's & Colitis Foundation as its Sample Management Services Provider for its Inflammatory Bowel Disease (IBD) CAPTURE and SIRQC Clinical Registries
BURLINGTON, Mass., June 4, 2024 /PRNewswire/ -- Azent... |
| May 21, 2024 | TREMFYA® (guselkumab) demonstrates superiority versus STELARA® (ustekinumab) in Phase 3 Crohn's disease program | Data from GALAXI 2 & 3 showed TREMFYA® was superior to STELARA ® in all pooled endoscopic endpoints
WASHINGTON, May 21, 2024 /PRNewswire/ -- Johnson & Johnson today announced the first Phase 3 results for TREMFYA® (guselkumab) in ad... |
| May 1, 2024 | US FDA approves high-concentration, citrate-free formulation of Cyltezo® (adalimumab-adbm) injection, Boehringer Ingelheim's interchangeable* biosimilar to Humira® | RIDGEFIELD, Conn., May 1, 2024 /PRNewswire/ -- Boehringer Ingelheim announced today that the U.S. Food and Drug Administration (FDA) has approved the high-concentration, citrate-free formulation of Cyltezo® (adalimumab-adbm), the company's ... |
| Nov 16, 2023 | What is ulcerative colitis? An expert explains what causes the inflammatory bowel disease and how to manage it | Our gut is the key to much of our body's overall health, which is why diseases like ulcerative colitis can be so detrimental.
Ulcerative colitis is one of the most common inflammatory bowel diseases. The Crohn's & Colitis Foundation est... |
| Oct 19, 2023 | Health | Crohn’s disease and colitis: Advocates strive to raise awareness, break stigma for ‘invisible’ illnesses | Lauren J. Mapp | The San Diego Union-Tribune
When Vista resident Michelle Harvey packed an overnight bag so her son could undergo testing at Rady Children’s Hospital in June 2020, she expected to return home the following day. Instead, Maso... |
| May 24, 2023 | Why does my butthole itch? 13 causes and how to remedy an itchy anus | Reviews Chevron icon It indicates an expandable section or menu, or sometimes previous / next navigation options.
Health Why does my butthole itch? 13 causes and how to remedy an itchy anus
Written by Adam Barnes
Updated
2023-05-24T19:03:14... |
| Apr 11, 2023 | Medibiofarma, participada por Inveready, recibe financiación de la “Crohn’s & Colitis Foundation” para desarrollar una nueva terapia antifibrótica | 11/04/2023
Nota de prensa
MEDIBIOFARMA, PARTICIPADA POR INVEREADY, RECIBE FINANCIACIÓN DE LA “CROHN’S & COLITIS FOUNDATION” ESTADOUNIDENSE PARA APOYAR EL DESARROLLO DE UNA NUEVA TERAPIA ANTIFIBRÓTICA PARA LA ENFERMEDAD INFLAMATORIA IN... |
| Feb 1, 2023 | MHRA Approves RINVOQ[®]▼ (upadacitinib) as First Oral Advanced Therapy to Treat Adults with Moderately to Severely Active Crohn's Disease | MHRA Approves RINVOQ[®]▼ (upadacitinib) as First Oral Advanced Therapy to Treat Adults with Moderately to Severely Active Crohn's Disease
Wed, Feb 01, 2023 16:00 CET Report this content
PRESS RELEASE - For UK Consumer Health, Medical and Tr... |
| Jan 5, 2023 | 4 reasons stress can cause weight loss and expert-approved tips to help keep your stressors in check | Reviews Chevron icon It indicates an expandable section or menu, or sometimes previous / next navigation options.
Health 4 reasons stress can cause weight loss and expert-approved tips to help keep your stressors in check
Written by Brooke ... |
| Jul 26, 2022 | MHRA Approves RINVOQ®▼ (upadacitinib) For the Treatment of Moderately to Severely Active Ulcerative Colitis in Adults | MHRA Approves RINVOQ®▼ (upadacitinib) For the Treatment of Moderately to Severely Active Ulcerative Colitis in Adults
Tue, Jul 26, 2022 17:03 CET Report this content
PRESS RELEASE - For UK medical and trade media only
Ulcerative colitis (UC... |
| Jul 26, 2022 | MHRA Approves RINVOQ®▼ (upadacitinib) For the Treatment of Moderately to Severely Active Ulcerative Colitis in Adults | MHRA Approves RINVOQ®▼ (upadacitinib) For the Treatment of Moderately to Severely Active Ulcerative Colitis in Adults
Tue, Jul 26, 2022 18:03 CET Report this content
PRESS RELEASE - For UK medical and trade media only
Ulcerative colitis (UC... |
| Jul 19, 2022 | Hygieacare® preferred colonoscopy prep for patients with Crohn's Disease or Colitis (IBD) in “Crohn’s and Colitis 360.” | odorless and acoustically protected HyGIeaCare experience
Patients clearly prefer HygiPrep over conservative prep for colonoscopy
The manuscript reporting on 343 successful HygiPrep® procedures on IBD patients was published by "Crohn's... |
| May 24, 2022 | Everest Medicines' Licensing Partner Pfizer Presents ELEVATE Pivotal Findings Demonstrating Etrasimod's Potentially Best-in-Class Profile in Ulcerative Colitis | SHANGHAI, May 24, 2022 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK) announced today that its licensing partner, Pfizer Inc. (NYSE: PFE) presented at Digestive Disease Week (DDW) 2022 detailed results from two pivotal studies that make u... |
| Feb 1, 2022 | AbbVie Showcases Its Leadership in Research in Inflammatory Bowel Diseases with New Analyses to be Presented at the 17th Congress of European Crohn's and Colitis Organization (ECCO) | NORTH CHICAGO, Ill., Feb. 1, 2022 /PRNewswire/ -- AbbVie (NYSE: ABBV) will present further analyses on HUMIRA® (adalimumab) and the investigational uses of risankizumab (SKYRIZI®) and upadacitinib (RINVOQ®) at the 17th Congress of European ... |
| Jan 12, 2022 | Coral and Crohn’s & Colitis Foundation Announce Precision Medicine Partnership for Inflammatory Bowel Disease | SAN FRANCISCO (PRWEB) January 12, 2022
Coral Genomics, a company developing technologies to experimentally represent the diversity of humanity's biology announced today that it has entered a partnership with the Crohn’s & Colitis Founda... |
| Dec 6, 2021 | Upadacitinib (RINVOQ®) Achieved Primary and Key Secondary Endpoints in First Phase 3 Induction Study in Patients with Crohn's Disease | NORTH CHICAGO, Ill., Dec. 6, 2021 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced positive top-line results from U-EXCEED, a Phase 3 induction study, showing upadacitinib (45 mg once daily) achieved both primary endpoints of clinical re... |
| Nov 30, 2021 | AbbVie Submits Application for Risankizumab (SKYRIZI®) in Moderate to Severe Crohn's Disease to European Medicines Agency (EMA) | NORTH CHICAGO, Ill., Nov. 30, 2021 /PRNewswire/ -- AbbVie (NYSE:ABBV) today announced it has submitted an application to the European Medicines Agency (EMA) seeking approval for risankizumab (SKYRIZI®, 600 mg intravenous (IV) induction and ... |
| Nov 17, 2021 | Johnson & Johnson : Janssen Reports Positive Topline Week 48 Phase 2 Results for TREMFYA® (guselkumab) in Adults With Moderately to Severely Active Crohn's Disease | SPRING HOUSE, PENNSYLVANIA, November 17, 2021 - The Janssen Pharmaceutical Companies of Johnson & Johnson today announced topline results from the Phase 2 GALAXI 1 clinical trial which showed rates of clinical remission (Crohn's Disease... |
| Oct 25, 2021 | Johnson & Johnson : New Analyses Suggest Favorable Results for STELARA® (ustekinumab) When Used as a First-Line Therapy for Bio-Naïve Patients with Moderately to Severely Active Crohn's Disease and Ulcerative Colitis | SPRING HOUSE, PENNSYLVANIA, October 25, 2021 - The Janssen Pharmaceutical Companies of Johnson & Johnson today announced data from two new analyses of STELARA® (ustekinumab) for the treatment of adults with moderately to severely active... |
| Oct 6, 2021 | Galapagos : announces completion of patient enrollment for DIVERSITY Phase 3 study with filgotinib in Crohn's Disease (Form 6-K) | Galapagos announces completion of patient enrollment for DIVERSITY Phase 3 study with filgotinib in Crohn's Disease
1,374 patients enrolled into the phase 3 studyacross 369 global sites
Topline data anticipated in H1 2023
Galapagos will ass... |
| Oct 4, 2021 | Galapagos : announces completion of patient enrollment for DIVERSITY Phase 3 study with filgotinib in Crohn's Disease | 1,374 patients enrolled into the phase 3 study across 369 global sites
Topline data anticipated in H1 2023
Galapagos will assume responsibility for the DIVERSITY study
Mechelen, Belgium; 4 October 2021, 07.01 CET; Galapagos NV (Euronext &am... |
| Oct 3, 2021 | AbbVie : to Showcase New Data at the United European Gastroenterology (UEG) Week Virtual 2021 | NORTH CHICAGO, Ill., Oct. 2, 2021 /PRNewswire/ -- AbbVie today announced new data on the investigational use of risankizumab (SKYRIZI®) in Crohn's disease, upadacitinib (RINVOQ®) in ulcerative colitis and HUMIRA® (adalimumab) in inflammator... |
| Sep 22, 2021 | Iterative Scopes : and Crohn's & Colitis Foundation Announce Partnership to Advance Next-Generation IBD Treatment | Iterative Scopes, a pioneer in the development of precision-based technologies for treating gastrointestinal diseases, announced today that it has entered into an AI-powered diagnostic tools partnership with the Crohns & Colitis Foundat... |
| Sep 21, 2021 | Biosimilar drugs gain ground in U.S., but concerns linger about when patients can switch | It took years for Elle Moxley to get a diagnosis that explained her crippling gastrointestinal pain and digestion problems, fatigue and hot, red rashes. But even after learning in 2016 that she had Crohn’s disease, a chronic inflammation of... |
| Jun 28, 2021 | AbbVie : Gastroenterology Pipeline to be Featured at the 16th Congress of European Crohn's and Colitis Organisation (ECCO) | NORTH CHICAGO, Ill., June 28, 2021 /PRNewswire/ -- AbbVie today announced new data on upadacitinib (RINVOQ®) in ulcerative colitis and risankizumab (SKYRIZI®) in Crohn's disease will be presented as oral presentations at the 16th Congress o... |
| Feb 22, 2021 | AbbVie : Second Phase 3 Induction Study Confirms Upadacitinib (RINVOQ™) Improved Clinical, Endoscopic and Histologic Outcomes in Ulcerative Colitis Patients | NORTH CHICAGO, Ill., Feb. 22, 2021 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced that upadacitinib (45 mg, once daily) met the primary endpoint of clinical remission (per Adapted Mayo Score) and all ranked secondary endpoints in the P... |
| Feb 10, 2021 | Be an Effective Partner in Your IBD Care | (Family Features) A lifelong diagnosis like inflammatory bowel disease (IBD) may feel overwhelming and confusing, but by working closely with your health care providers, you can work toward managing the disease and improving your quality of... |
| Feb 10, 2021 | Be an Effective Partner in Your IBD Care | (Family Features) A lifelong diagnosis like inflammatory bowel disease (IBD) may feel overwhelming and confusing, but by working closely with your health care providers, you can work toward managing the disease and improving your quality of... |
| Jan 27, 2021 | How to Be an Effective Partner in Your IBD Care | (Family Features) A lifelong diagnosis like inflammatory bowel disease (IBD) may feel overwhelming and confusing, but by working closely with your health care providers, you can work toward managing the disease and improving your quality of... |
| Jan 27, 2021 | How to Be an Effective Partner in Your IBD Care | (Family Features) A lifelong diagnosis like inflammatory bowel disease (IBD) may feel overwhelming and confusing, but by working closely with your health care providers, you can work toward managing the disease and improving your quality of... |
| Jan 25, 2021 | LifeArc working with the Crohn’s & Colitis Foundation to develop a prognostic test for Crohn’s disease in children | A new partnership between LifeArc and the US-based Crohn’s & Colitis Foundation (Foundation) aims to progress encouraging research that could help to advance a promising new prognostic test closer to the clinic. The goal is to help deli... |
| Jan 21, 2021 | Biomica Announces Participation at the Crohn's & Colitis Congress® January 21-24, 2021 (Virtual Conference)
USA - English
USA - English | |
| Dec 8, 2020 | Create a plan: Working with a doctor to help manage a chronic inflammatory condition | (BPT) - Content sponsored and provided by Pfizer. Pfizer asked Stephanie to share her experience and compensated her for her time.
Stephanie was excited about starting her first job as a dog groomer. However, her plans changed during a fami... |
| Dec 8, 2020 | Create a plan: Working with a doctor to help manage a chronic inflammatory condition | (BPT) - Content sponsored and provided by Pfizer. Pfizer asked Stephanie to share her experience and compensated her for her time.
Stephanie was excited about starting her first job as a dog groomer. However, her plans changed during a fami... |
| Nov 17, 2020 | The Symptoms of UC May Impact People Both Physically and Emotionally: Here’s How to Begin Taking Back Some Control | (BPT) - Imagine having the worst anxiety whenever you leave the house because you never know when you're going to be driving or walking and the urge to go to the bathroom is going to hit you. That is what it can be like for some people livi... |
| Dec 4, 2018 | PredictImmune and the Crohn’s & Colitis Foundation announce a joint study | PredictImmune and the Crohn’s & Colitis Foundation announce a joint study
04-12-2018
PredictImmune, developers of pioneering prognostic tools for guiding treatment options and improving patient outcomes in immune-mediated diseases, toda... |
| How AJ Vaynerchuk is fighting burnout among his 25 employees | At VaynerSports, employees get unlimited time off and are required to take at least two weeks of vacation a year, founder AJ Vaynerchuk said. Courtesy of VaynerSports This story is available exclusively to Insider subscribers. Become an Ins... |
| 'High-Risk' Sex Could Raise Odds for Crohn's, Colitis in Gay Men
Was this page helpful?
Was this page helpful?
Was this page helpful?
Was this page helpful?
Was this page helpful?
Was this page helpful?
Was this page helpful?
Was this page helpful?
Was this page helpful?
Was this page ... | TUESDAY, Sept. 20, 2022 (HealthDay News) -- Compared with heterosexual men, gay men are more than twice as likely to develop inflammatory bowel disease (IBD) when engaging in “high-risk” sexual behavior, new research shows.
The definition o... |
